Mark C. Hammer

1.0k total citations
34 papers, 808 citations indexed

About

Mark C. Hammer is a scholar working on Epidemiology, Pharmacology and Molecular Medicine. According to data from OpenAlex, Mark C. Hammer has authored 34 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 9 papers in Pharmacology and 8 papers in Molecular Medicine. Recurrent topics in Mark C. Hammer's work include Antibiotic Resistance in Bacteria (8 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers) and Urban Transport and Accessibility (4 papers). Mark C. Hammer is often cited by papers focused on Antibiotic Resistance in Bacteria (8 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers) and Urban Transport and Accessibility (4 papers). Mark C. Hammer collaborates with scholars based in United States, Germany and Czechia. Mark C. Hammer's co-authors include Aldona L. Baltch, Raymond P. Smith, Anne T. McCartt, John Rohrbaugh, M. Voelker, Poul Michelsen, M Shayegani, David Wu, Christopher Maylahn and Edward C. Waltz and has published in prestigious journals such as Journal of Clinical Microbiology, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Mark C. Hammer

34 papers receiving 719 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark C. Hammer United States 15 192 172 127 105 102 34 808
Mojtaba Sehat Iran 18 79 0.4× 40 0.2× 45 0.4× 77 0.7× 38 0.4× 78 766
Michael Singleton United States 17 179 0.9× 11 0.1× 9 0.1× 106 1.0× 94 0.9× 51 1.2k
Gordon R. Reeve United States 11 525 2.7× 27 0.2× 6 0.0× 18 0.2× 64 0.6× 20 915
Lida Jarahi Iran 14 122 0.6× 9 0.1× 43 0.3× 12 0.1× 59 0.6× 137 887
Jocelyn Y. Ang United States 17 148 0.8× 5 0.0× 79 0.6× 12 0.1× 94 0.9× 48 734
Chris H. Miller United States 23 82 0.4× 89 0.5× 8 0.1× 3 0.0× 64 0.6× 87 2.0k
Valeria Di Onofrio Italy 19 173 0.9× 15 0.1× 22 0.2× 3 0.0× 34 0.3× 65 1.0k
D. Mortiboy United Kingdom 11 205 1.1× 9 0.1× 111 0.9× 6 0.1× 96 0.9× 15 487
Anoop Verma India 16 98 0.5× 5 0.0× 22 0.2× 51 0.5× 17 0.2× 67 680
Rajeev Aravindakshan India 15 56 0.3× 5 0.0× 50 0.4× 30 0.3× 17 0.2× 89 654

Countries citing papers authored by Mark C. Hammer

Since Specialization
Citations

This map shows the geographic impact of Mark C. Hammer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Hammer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Hammer more than expected).

Fields of papers citing papers by Mark C. Hammer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Hammer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Hammer. The network helps show where Mark C. Hammer may publish in the future.

Co-authorship network of co-authors of Mark C. Hammer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Hammer. A scholar is included among the top collaborators of Mark C. Hammer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Hammer. Mark C. Hammer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rowe, Kirsten, et al.. (2022). Naloxone administration by law enforcement officers in New York State (2015–2020). Harm Reduction Journal. 19(1). 102–102. 19 indexed citations
2.
McKnight, Courtney, et al.. (2017). The New York 911 Good Samaritan Law and Opioid Overdose Prevention Among People Who Inject Drugs. World Medical & Health Policy. 9(3). 318–340. 20 indexed citations
3.
Voelker, M. & Mark C. Hammer. (2011). Dissolution and pharmacokinetics of a novel micronized aspirin formulation. Inflammopharmacology. 20(4). 225–231. 40 indexed citations
4.
McCartt, Anne T., et al.. (2000). Factors associated with falling asleep at the wheel among long-distance truck drivers. Accident Analysis & Prevention. 32(4). 493–504. 230 indexed citations
5.
McCartt, Anne T., et al.. (1998). RESEARCH ON THE SCOPE AND NATURE OF FATIGUED DRIVING AMONG TRUCK DRIVERS IN NEW YORK STATE. 2 indexed citations
6.
McCartt, Anne T., et al.. (1997). Work and Sleep/Rest Factors Associated With Driving While Drowsy Experiences Among Long-Distance Truck Drivers. 41. 95–108. 9 indexed citations
7.
McCartt, Anne T., et al.. (1996). The scope and nature of the drowsy driving problem in New York state. Accident Analysis & Prevention. 28(4). 511–517. 7 indexed citations
8.
McCartt, Anne T., et al.. (1996). An evaluation of the use of in-vehicle videotaping of DWI suspects. 1 indexed citations
9.
Baltch, Aldona L., et al.. (1991). Synergy with cefsulodin or piperacillin and three aminoglycosides or aztreonam against aminoglycoside resistant strains of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 27(6). 801–808. 6 indexed citations
10.
Bopp, Lawrence H., Aldona L. Baltch, Mark C. Hammer, et al.. (1991). Isolation and characterization of a transposon-induced cytotoxin-deficient mutant of Pseudomonas aeruginosa. Infection and Immunity. 59(2). 708–711. 3 indexed citations
11.
Valdes, Joaquin, Aldona L. Baltch, Raymond P. Smith, Mark C. Hammer, & William J. Ritz. (1990). The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 25(4). 575–584. 14 indexed citations
12.
Baltch, Aldona L., et al.. (1989). Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions. Journal of Antimicrobial Chemotherapy. 23(1). 37–41. 47 indexed citations
13.
Baltch, Aldona L., et al.. (1988). Comparative in-vitro activities of A-56268 (TE-031) and erythromycin against 306 clinical isolates. Journal of Antimicrobial Chemotherapy. 21(5). 565–570. 10 indexed citations
14.
Smith, Raymond P., et al.. (1988). In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains. Antimicrobial Agents and Chemotherapy. 32(9). 1450–1455. 20 indexed citations
15.
Baltch, Aldona L., et al.. (1987). Production of cytotoxin by clinical strains of Pseudomonas aeruginosa. Canadian Journal of Microbiology. 33(2). 104–111. 11 indexed citations
16.
Smith, Raymond P., et al.. (1987). The effect of diabetes mellitus on chemotactic and bactericidal activity of human polymorphonuclear leukocytes. Diabetes Research and Clinical Practice. 4(1). 27–35. 61 indexed citations
17.
Baltch, Aldona L., Mark C. Hammer, Raymond P. Smith, et al.. (1985). Effects of Pseudomonas aeruginosa cytotoxin on human serum and granulocytes and their microbicidal, phagocytic, and chemotactic functions. Infection and Immunity. 48(2). 498–506. 20 indexed citations
18.
Baltch, Aldona L., et al.. (1982). Comparative inhibitory and bactericidal activities of moxalactam and seven other antibiotics against 520 clinical isolates including 65 multi-drug resistant strains. Journal of Antimicrobial Chemotherapy. 10(1). 11–24. 7 indexed citations
19.
Hammer, Mark C., et al.. (1981). Pseudomonas aeruginosa: quantitation of maximum phagocytic and bactericidal capabilities of normal human granulocytes.. PubMed. 98(6). 938–48. 24 indexed citations
20.
Smith, Raymond P., et al.. (1981). Concentration of cefaclor in human prostatic tissue. The American Journal of the Medical Sciences. 281(1). 19–24. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mojtaba Sehat Breakdown of academic impact, for papers by Michael Singleton Breakdown of academic impact, for papers by Gordon R. Reeve Breakdown of academic impact, for papers by Lida Jarahi Breakdown of academic impact, for papers by Jocelyn Y. Ang Breakdown of academic impact, for papers by Chris H. Miller Breakdown of academic impact, for papers by Valeria Di Onofrio Breakdown of academic impact, for papers by D. Mortiboy Breakdown of academic impact, for papers by Anoop Verma Breakdown of academic impact, for papers by Rajeev Aravindakshan
Rankless by CCL
2026